For people whose lymphoma returns after chemotherapy, the most advanced option now uses their own immune system—if they can get it in time. CAR-T therapy, which reprograms a patient’s white blood cells to attack tumour cells, has changed the outlook for blood cancers that don’t respond to standard treatments. But the promise of this personalised approach is often limited by practical barriers: where you live, how quickly the cells can be made, and whether you can afford the journey or the treatment itself.
In 2026, the FDA approved the first in vivo CAR-T candidate from China for clinical trials in the US, marking a milestone in global cell therapy innovation.
Since Bill Ludwig’s remission in 2010, when he became the first patient to receive CAR-T in a US clinical trial, the therapy has moved from experimental to standard care for certain blood cancers. By 30 June 2026, the FDA had approved seven CAR-T therapies for blood cancers. Lisocabtagene maraleucel (Breyanzi) received an expanded indication for relapsed or refractory marginal zone lymphoma after at least two prior therapies, as reported in the Cancer Progress Report 2026 from the American Association for Cancer Research. The FDA also gave full approval to TECARTUS for relapsed or refractory mantle cell lymphoma in April 2026 and lifted a previous YESCARTA label restriction for primary CNS lymphoma in February 2026.
But the science is only part of the story. In Spain, lymphoma is expected to affect 13,000 new patients in 2026, with more than 60 subtypes that each need different treatment plans. Diffuse large B-cell lymphoma moves quickly and needs urgent care, while follicular lymphoma can be managed more slowly. Still, the most common sign—persistent, growing lymph nodes—often means patients and doctors are racing against time and the limits of the health system.
In May 2026, the FDA granted accelerated approval to sonrotoclax (Beqalzi) for adults with relapsed or refractory mantle cell lymphoma after at least two prior therapies, including a BTK inhibitor. This provides an important alternative in the same clinical setting where CAR-T access remains limited.
Across Europe, CAR-T is available in countries like England, France, Germany, Spain, and Italy, but national reimbursement rules and the type of specialist centre shape the real path to treatment. In the United States, one CAR-T for B-cell acute lymphoblastic leukaemia is available in over 70 centres, showing how much specialist networks matter for who gets treated and who waits.
The treatment itself is demanding. After lymphocyte collection and manufacturing, patients get preparatory chemotherapy before the modified cells are infused. Most need to be admitted to hospital, since the therapy requires staff and facilities trained to handle both the infusion and possible complications. Gloria Iacoboni of Hospital Universitario Vall d'Hebron says there are efforts to shorten hospital stays and eventually move more treatment outside the hospital, but for now, the infrastructure is still a major barrier.
Research is moving the field forward. Scientists are working on new CAR-T receptors to target different tumours, testing allogeneic (donor-derived) versions to speed up manufacturing, and exploring in vivo approaches that could deliver genetic instructions directly inside the body. On 16 September 2026, the FDA cleared an IND for IASO208, a CD20-targeted in vivo CAR-T candidate for adults with relapsed or refractory B-cell non-Hodgkin lymphoma, aiming to avoid the need for external cell manufacturing. These advances are still experimental, but they point to a future where access might depend less on geography and logistics.
CAR-T has changed what is possible for relapsed blood cancers, but its impact depends not just on clinical results, but on how many patients can actually get the therapy before their window closes. The next challenge is not scientific—it is systemic. Until health systems can deliver this personalised treatment more equally, the fight against lymphoma will remain as much about access as about biology.
